Product
GRC 54276
1 clinical trial
2 indications
Indication
Advanced Solid TumorIndication
lymphomaClinical trial
A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas.Status: Recruiting, Estimated PCD: 2027-07-30